243 related articles for article (PubMed ID: 15952098)
1. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Furuta T; Sagehashi Y; Shirai N; Sugimoto M; Nakamura A; Kodaira M; Kenmotsu K; Nagano M; Egashira T; Ueda K; Yoneyama M; Ohashi K; Ishizaki T; Hishida A
Clin Gastroenterol Hepatol; 2005 Jun; 3(6):564-73. PubMed ID: 15952098
[TBL] [Abstract][Full Text] [Related]
2. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
Furuta T; Shirai N; Xiao F; El-Omar EM; Rabkin CS; Sugimura H; Ishizaki T; Ohashi K
Clin Gastroenterol Hepatol; 2004 Jan; 2(1):22-30. PubMed ID: 15017629
[TBL] [Abstract][Full Text] [Related]
4. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
[TBL] [Abstract][Full Text] [Related]
5. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
Furuta T; Sugimoto M; Shirai N; Matsushita F; Nakajima H; Kumagai J; Senoo K; Kodaira C; Nishino M; Yamade M; Ikuma M; Watanabe H; Umemura K; Ishizaki T; Hishida A
Aliment Pharmacol Ther; 2007 Sep; 26(5):693-703. PubMed ID: 17697203
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
7. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
[TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
[TBL] [Abstract][Full Text] [Related]
10. Gastric Juice-Based Real-Time PCR for Tailored
Peng X; Song Z; He L; Lin S; Gong Y; Sun L; Zhao F; Gu Y; You Y; Zhou L; Zhang J
Int J Med Sci; 2017; 14(6):595-601. PubMed ID: 28638276
[TBL] [Abstract][Full Text] [Related]
11. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
Sapone A; Vaira D; Trespidi S; Perna F; Gatta L; Tampieri A; Ricci C; Cantelli-Forti G; Miglioli M; Biagi GL; Paolini M
Am J Gastroenterol; 2003 May; 98(5):1010-5. PubMed ID: 12809821
[TBL] [Abstract][Full Text] [Related]
12. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
[TBL] [Abstract][Full Text] [Related]
13. [Development and clinical application of invader assay--detection of resistant mutation to clarithromycin in Helicobacter pylori].
Egashira T
Rinsho Byori; 2006 Feb; 54(2):176-83. PubMed ID: 16548239
[TBL] [Abstract][Full Text] [Related]
14. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
He XX; Zhao YH; Hao YT
Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
[TBL] [Abstract][Full Text] [Related]
15. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
[TBL] [Abstract][Full Text] [Related]
16. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
[TBL] [Abstract][Full Text] [Related]
17. Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
Isomoto H; Inoue K; Furusu H; Nishiyama H; Shikuwa S; Omagari K; Mizuta Y; Murase K; Murata I; Kohno S
Helicobacter; 2003 Apr; 8(2):111-9. PubMed ID: 12662378
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Hokari K; Sugiyama T; Kato M; Saito M; Miyagishima T; Kudo M; Nishikawa K; Ishizuka J; Komatsu Y; Mizushima T; Kagaya H; Hige S; Takeda H; Asaka M
Aliment Pharmacol Ther; 2001 Sep; 15(9):1479-84. PubMed ID: 11552922
[TBL] [Abstract][Full Text] [Related]
19. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Jul; 80(1):41-50. PubMed ID: 16815316
[TBL] [Abstract][Full Text] [Related]
20. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
